Correction to “Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long‐Term Outcome”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNonmelanoma Skin Cancer Studies · Vascular Malformations and Hemangiomas · Genetic and rare skin diseases.
N. C. C. Lucas, C. Horgan, O. Mustafa, et al., “Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long‐Term Outcome,” JIMD Reports 66, no. 5 (2025): e70041, https://doi.org/10.1002/jmd2.70041.
The key points are incorrect in the published article:
Key Points
- This case series reported two cases of type 2/3 Farber's Lipogranulomatosis (FL) treated with Haematopoietic Stem Cell Transplant (HSCT).
- Case 1 was a 3y11m old girl who had a matched sibling transplant. She had a complicated transplant course including infections and pulmonary oedema. By day 450 post transplant her ESR had normalised and nodules had decreased significantly in size.
- Case 2 was a 3y10m old boy who had an unrelated donor transplant. By day 337 he had significant improvement of his subcuntaneous nodules and reduction of his ESR.
- This case series emphasizes that cases of type 2/3 FL can be treated with FL and provided useful information for us in our treatment decision making process.
The correct key points are shown below:
Key Points
- We present a 15 month old who was diagnosed with Farber's Lipogranulomatosis (FL) without neurological involvement
- This case illustrates that a step‐wise approach to management of FL utilising Tocilizumab followed by haematopoietic stem cell transplant
- A stepwise approach allows assessment of neurological status and time to aid in transplant decisions in these complex patients.
We apologize for this error.